PA21, a new iron-based noncalcium phosphate binder, prevents vascular calcification in chronic renal failure rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 346, Issue 2, 2013, Pages 281-289

  Phan, Olivier ^a   Maillard, Marc ^a   Peregaux, Christine ^a   Mordasini, David ^a   Stehle, Jean Christophe ^a   Funk, Felix ^b   Burnier, Michel ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Vifor (International) Ltd   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CALCIUM CARBONATE; CREATININE; FIBROBLAST GROWTH FACTOR 23; PA21; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL CALCIFICATION; BODY WEIGHT; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; HEART RATE; HYPERPARATHYROIDISM; NONHUMAN; PHOSPHATE BLOOD LEVEL; PHOSPHATURIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT;

ADENINE; ANIMALS; AORTA; BLOOD PRESSURE; CALCIUM; CALCIUM CARBONATE; FERRIC COMPOUNDS; FIBROBLAST GROWTH FACTORS; HEART RATE; KIDNEY FAILURE, CHRONIC; MALE; PARATHYROID HORMONE; PHOSPHORUS; RATS; RATS, WISTAR; VASCULAR CALCIFICATION;

EID: 84880399741     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.204792     Document Type: Article

References (52)

1. Bendich A (2001) Calcium supplementation and iron status of females. Nutrition 17: 46-51.
2. Bleskestad IH, Bergrem H, Hartmann A, Godang K, and Gøransson LG (2012) Fibroblast growth factor 23 and parathyroid hormone after treatment with active vitamin D and sevelamer carbonate in patients with chronic kidney disease stage 3b, a randomized crossover trial. BMC Nephrol 13:49.
3. Chen NX, Chen X, O'Neill KD, Atkinson SJ, and Moe SM (2010) RhoA/Rho kinase (ROCK) alters fetuin-A uptake and regulates calcification in bovine vascular smooth muscle cells (BVSMC). Am J Physiol Renal Physiol 299:F674-F680.
4. Chertow GM, Burke SK, and Raggi P; Treat to Goal Working Group (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-252.
5. Cozzolino M, Dusso AS, Liapis H, Finch J, Lu Y, Burke SK, and Slatopolsky E (2002) The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats. J Am Soc Nephrol 13:2299-2308.
6. Cozzolino M, Staniforth ME, Liapis H, Finch J, Burke SK, Dusso AS, and Slatopolsky E (2003) Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int 64:1653-1661.
7. Damment S, Secker R, Shen V, Lorenzo V, and Rodriguez M (2011) Long-term treatment with lanthanum carbonate reduces mineral and bone abnormalities in rats with chronic renal failure. Nephrol Dial Transplant 26:1803-1812.
8. Foley RN, Parfrey PS, and Sarnak MJ (1998) Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 9(12, Suppl)S16-S23.
9. Geisser P and Philipp E (2010) PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease. Clin Nephrol 74:4-11.
10. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, and Greaser L, et al. (2000) Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478-1483.
11. Guilgen G, Werneck ML, de Noronha L, Martins AP, Varela AM, Nakao LS, and Pecoits-Filho R (2011) Increased calcification and protein nitration in arteries of chronic kidney disease patients. Blood Purif 32:296-302.
12. Gutiérrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, and Christenson R, et al. (2009) Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119:2545-2552.
13. Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, and Jüppner H, et al. (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359:584-592.
14. Haller H, Lindschau C, Quass P, Distler A, and Luft FC (1995) Differentiation of vascular smooth muscle cells and the regulation of protein kinase C-alpha. Circ Res 76:21-29.
15. Hergesell O and Ritz E (1999) Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients. Nephrol Dial Transplant 14:863-867.
16. Hirata M, Katsumata K, Endo K, Fukushima N, Ohkawa H, and Fukagawa M (2003) In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3. Nephrol Dial Transplant 18:1770-1776.
17. Hruska K, Mathew S, Lund R, Fang Y, and Sugatani T (2011) Cardiovascular risk factors in chronic kidney disease: does phosphate qualify? quest Kidney Int Suppl (121):S9-S13.
18. Hughes AD (1995) Calcium channels in vascular smooth muscle cells. J Vasc Res 32: 353-370.
19. Isakova T, Gutiérrez OM, Smith K, Epstein M, Keating LK, Jüppner H, and Wolf M (2011) Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant 26:584-591.
20. Jean G, Bresson E, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, and Chazot C (2009) Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant 24:948-955.
21. Kapustin AN, Davies JD, Reynolds JL, McNair R, Jones GT, Sidibe A, Schurgers LJ, Skepper JN, Proudfoot D, and Mayr M, et al. (2011) Calcium regulates key components of vascular smooth muscle cell-derived matrix vesicles to enhance mineralization. Circ Res 109:e1-e12.
22. Katsumata K, Kusano K, HirataM, Tsunemi K, Nagano N, Burke SK, and Fukushima N (2003) Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. Kidney Int 64:441-450.
23. Massy ZA, Ivanovski O, Nguyen-Khoa T, Angulo J, Szumilak D, Mothu N, Phan O, Daudon M, Lacour B, and Drüeke TB, et al. (2005) Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein E knockout mice. J Am Soc Nephrol 16:109-116.
24. Mattson DL (1998) Long-term measurement of arterial blood pressure in conscious mice. Am J Physiol 274:R564-R570.
25. Mattson DL, Lu S, Nakanishi K, Papanek PE, and Cowley AW, Jr (1994) Effect of chronic renal medullary nitric oxide inhibition on blood pressure. Am J Physiol 266:H1918-H1926.
26. Mizobuchi M, Ogata H, Koiwa F, Kinugasa E, and Akizawa T (2009) Vitamin D and vascular calcification in chronic kidney disease. Bone 45 (Suppl 1):S26-S29.
27. Moe SM and Chen NX (2008) Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol 19:213-216.
28. Moe SM, O'Neill KD, Duan D, Ahmed S, Chen NX, Leapman SB, Fineberg N, and Kopecky K (2002) Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 61:638-647.
29. Neven E, Dams G, Postnov A, Chen B, De Clerck N, De Broe ME, D'Haese PC, and Persy V (2009) Adequate phosphate binding with lanthanum carbonate attenuates arterial calcification in chronic renal failure rats. Nephrol Dial Transplant 24:1790-1799.
30. Neven E, Persy V, Dauwe S, De Schutter T, De Broe ME, and D'Haese PC (2010) Chondrocyte rather than osteoblast conversion of vascular cells underlies medial calcification in uremic rats. Arterioscler Thromb Vasc Biol 30:1741-1750.
31. Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, Carvalho AB, Jorgetti V, Canziani ME, and Moysés RM (2010) Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol 5:286-291.
32. Persy V, Postnov A, Neven E, Dams G, De Broe M, D'Haese P, and De Clerck N (2006a) High-resolution X-ray microtomography is a sensitive method to detect vascular calcification in living rats with chronic renal failure. Arterioscler Thromb Vasc Biol 26:2110-2116.
33. Persy VP, Behets GJ, Bervoets AR, De Broe ME, and D'Haese PC (2006b) Lanthanum: a safe phosphate binder. Semin Dial 19:195-199.
34. Phan O, Ivanovski O, Nguyen-Khoa T, Mothu N, Angulo J, Westenfeld R, Ketteler M, Meert N, Maizel J, and Nikolov IG, et al. (2005) Sevelamer prevents uremiaenhanced atherosclerosis progression in apolipoprotein E-deficient mice. Circulation 112:2875-2882.
35. Phan O, Ivanovski O, Nikolov IG, Joki N, Maizel J, Louvet L, Chasseraud M, Nguyen-Khoa T, Lacour B, and Drüeke TB, et al. (2008) Effect of oral calcium carbonate on aortic calcification in apolipoprotein E-deficient (apoE-/-) mice with chronic renal failure. Nephrol Dial Transplant 23:82-90.
36. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, and Chertow GM (2002) Cardiac calcification in adult hemodialysis patients. A link between endstage renal disease and cardiovascular disease? J Am Coll Cardiol 39:695-701.
37. Rodriguez-Ortiz ME, Lopez I, Muñoz-Castañeda JR, Martinez-Moreno JM, Ramírez AP, Pineda C, Canalejo A, Jaeger P, Aguilera-Tejero E, and Rodriguez M, et al. (2012) Calcium deficiency reduces circulating levels of FGF23. J Am Soc Nephrol 23:1190-1197.
38. Scialla JJ, Lau WL, Reilly MP, Isakova T, Yang HY, Crouthamel MH, Chavkin NW, Rahman M, Wahl P, and Amaral AP, et al. (2013) Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int DOI: 10.1038/ ki.2013.3 [published ahead of print]
39. Shanahan CM, Cary NRB, Salisbury JR, Proudfoot D, Weissberg PL, and Edmonds ME (1999) Medial localization of mineralization-regulating proteins in association with Mönckeberg's sclerosis: evidence for smooth muscle cell-mediated vascular calcification. Circulation 100:2168-2176.
40. Shigematsu T and Negi S; COLC Research Group (2012) Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH (COLC Study). Nephrol Dial Transplant 27:1050-1054.
41. Six I, Maizel J, Barreto FC, Rangrez AY, Dupont S, Slama M, Tribouilloy C, Choukroun G, Mazière JC, and Bode-Boeger S, et al. (2012) Effects of phosphate on vascular function under normal conditions and influence of the uraemic state. Cardiovasc Res 96:130-139.
42. Soriano S, Ojeda R, Rodríguez M, Almadén Y, Rodríguez M,Martín-Malo A, and Aljama P (2013) The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients. Clin Nephrol [published ahead of print].
43. Sowers KM and Hayden MR (2010) Calcific uremic arteriolopathy: pathophysiology, reactive oxygen species and therapeutic approaches. Oxid Med Cell Longev 3: 109-121.
44. Spasovski GB, Sikole A, Gelev S, Masin-Spasovska J, Freemont T, Webster I, Gill M, Jones C, De Broe ME, and D'Haese PC (2006) Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant 21:2217-2224.
45. Spiegel DM and Brady K (2012) Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets. Kidney Int 81: 1116-1122.
46. Srivaths PR, Goldstein SL, Silverstein DM, Krishnamurthy R, and Brewer ED (2011) Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients. Pediatr Nephrol 26:945-951.
47. Tamagaki K, Yuan Q, Ohkawa H, Imazeki I, Moriguchi Y, Imai N, Sasaki S, Takeda K, and Fukagawa M (2006) Severe hyperparathyroidism with bone abnormalities and metastatic calcification in rats with adenine-induced uraemia. Nephrol Dial Transplant 21:651-659.
48. Whitesall SE, Hoff JB, Vollmer AP, and D'Alecy LG (2004) Comparison of simultaneous measurement of mouse systolic arterial blood pressure by radiotelemetry and tail-cuff methods. Am J Physiol Heart Circ Physiol 286:H2408-H2415.
49. Wüthrich RP, Chonchol M, Covic A, Gaillard S, Chong E, and Tumlin JA (2013) Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol 8:280-289.
50. Yasin A, Liu D, Chau L, Madrenas J, and Filler G (2013) Fibroblast growth factor-23 and calcium phosphate product in young chronic kidney disease patients: a crosssectional study. BMC Nephrol 14:39.
51. Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, and Yenicesu M, et al. (2012) Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial. Am J Kidney Dis 59:177-185.
52. Yokozawa T, Zheng PD, Oura H, and Koizumi F (1986) Animal model of adenineinduced chronic renal failure in rats. Nephron 44:230-234.